{"id":"ai-adjuvant-therapy","safety":{"commonSideEffects":[]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"anthropic-haiku","explanation":"This investigational approach leverages machine learning algorithms to analyze patient data, tumor characteristics, and treatment response patterns to guide adjuvant therapy selection and dosing. The goal is to improve outcomes by tailoring adjuvant regimens to individual patient and tumor profiles, potentially reducing unnecessary toxicity while maximizing efficacy.","oneSentence":"AI adjuvant therapy uses artificial intelligence to optimize and personalize adjuvant treatment strategies in cancer patients.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T03:20:31.066Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Adjuvant cancer therapy optimization (indication-specific application pending)"}]},"trialDetails":[{"nctId":"NCT06492616","phase":"PHASE3","title":"A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence","status":"RECRUITING","sponsor":"Stemline Therapeutics, Inc.","startDate":"2024-09-27","conditions":"Breast Cancer","enrollment":4220},{"nctId":"NCT06930859","phase":"","title":"Non-interventional Study to Assess the Effectiveness and Safety of Ribociclib in the Adjuvant Therapy of Hormone Receptor Positive (HR+) HER2-negative Stage II and III Breast Cancer in Real Clinical Practice in Russia","status":"RECRUITING","sponsor":"Novartis Pharmaceuticals","startDate":"2025-12-22","conditions":"Breast Cancer","enrollment":2766},{"nctId":"NCT06830720","phase":"","title":"A Non-interventional Study for Kisqali (Ribociclib) in Combination With an Aromatase Inhibitor for Adjuvant Treatment in Patients With HR+/HER2- Early Breast Cancer at High Risk of Recurrence","status":"RECRUITING","sponsor":"Novartis Pharmaceuticals","startDate":"2025-02-20","conditions":"Breast Neoplasms","enrollment":3250},{"nctId":"NCT05879926","phase":"PHASE3","title":"Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25","status":"RECRUITING","sponsor":"NRG Oncology","startDate":"2023-08-31","conditions":"Breast Cancer","enrollment":3960},{"nctId":"NCT05774951","phase":"PHASE3","title":"A Study of Camizestrant in ER+/HER2- Early Breast Cancer After at Least 2 Years of Standard Adjuvant Endocrine Therapy","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2023-03-31","conditions":"Breast Cancer, Early Breast Cancer","enrollment":4300},{"nctId":"NCT06905301","phase":"","title":"Implementation Study to Describe and Compare Retention Rate and Adherence to Adjuvant Therapy With Ribociclib With and Without Usage of Mobile Application in Patients With HR+ HER2-negative Stage II and III Breast Cancer in Real-world Practice","status":"RECRUITING","sponsor":"Novartis Pharmaceuticals","startDate":"2026-01-23","conditions":"Breast Cancer","enrollment":240},{"nctId":"NCT06127979","phase":"NA","title":"A Study of Changes in Ki67 Expression in People With Breast Cancer Receiving Endocrine Therapy Before Surgery","status":"RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2023-11-06","conditions":"Breast Cancer","enrollment":42},{"nctId":"NCT07071038","phase":"PHASE2","title":"Evaluating the Use of a Medication 'Switch' vs Guideline-directed Interventions for Relieving Side Effects of Aromatase Inhibitors Among Breast Cancer Patients","status":"RECRUITING","sponsor":"Dartmouth-Hitchcock Medical Center","startDate":"2025-10-17","conditions":"Breast Cancer, Adjuvant Treatment, Early Stage Breast Cancer","enrollment":62},{"nctId":"NCT02912559","phase":"PHASE3","title":"Combination Chemotherapy With or Without Atezolizumab in Treating Patients With Stage III Colon Cancer and Deficient DNA Mismatch Repair","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2017-10-16","conditions":"Colon Adenocarcinoma, DNA Repair Disorder, Lynch Syndrome","enrollment":712},{"nctId":"NCT06970912","phase":"PHASE2","title":"ctDNA-Guided De-Escalation of Adjuvant Chemotherapy With Dalpiciclib in HR-Positive/HER2-Negative Breast Cancer","status":"RECRUITING","sponsor":"Peking University People's Hospital","startDate":"2025-08-01","conditions":"Hormone Receptor-Positive Breast Cancer, High-risk Breast Cancer, Early-Stage Breast Cancer","enrollment":393},{"nctId":"NCT07328087","phase":"EARLY_PHASE1","title":"COLONYVAQ™, a Quantum-Classical Guided Personalized Neoantigen Vaccine for MSS Stage III Colorectal Cancer","status":"RECRUITING","sponsor":"Biogenea Pharmaceuticals Ltd.","startDate":"2026-02-02","conditions":"Colorectal Cancer Metastatic, Colorectal Cancer Stage III, Colorectal Cancer Stage IV","enrollment":12},{"nctId":"NCT05122377","phase":"","title":"RWE About QOL and Compliance of Patients With OFS in China","status":"COMPLETED","sponsor":"Fudan University","startDate":"2022-03-01","conditions":"Breast Cancer, Quality of Life, Hormone Receptor-positive Breast Cancer","enrollment":562},{"nctId":"NCT07285434","phase":"EARLY_PHASE1","title":"Clinical Study of the Therapeutic Effectiveness of In-silico-Designed, Machine Learning Inspired, and Quantum-molecularly Coupled Personalized Neoantigenic Vaccines Microlyvaq™ in Patients With Advanced Non-small Cell Lung Cancer","status":"ENROLLING_BY_INVITATION","sponsor":"Biogenea Pharmaceuticals Ltd.","startDate":"2026-02-02","conditions":"NSCLC (Non-small Cell Lung Cancer), Squamous Lung Cancer With FGFR1 Amplification, Non-Squamous Non Small Cell Lung Cancer","enrollment":90},{"nctId":"NCT04329494","phase":"PHASE1","title":"PIPAC for the Treatment of Peritoneal Carcinomatosis in Patients With Ovarian, Uterine, Appendiceal, Colorectal, or Gastric Cancer","status":"RECRUITING","sponsor":"City of Hope Medical Center","startDate":"2020-08-21","conditions":"Clinical Stage IV Gastric Cancer AJCC v8, Clinical Stage IVA Gastric Cancer AJCC v8, Clinical Stage IVB Gastric Cancer AJCC v8","enrollment":49},{"nctId":"NCT05836584","phase":"PHASE2","title":"Testing Immunotherapy (Atezolizumab) With or Without Chemotherapy in Locoregional MSI-H/dMMR Gastric and Gastroesophageal Junction (GEJ) Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2023-12-06","conditions":"Clinical Stage I Gastric Cancer AJCC v8, Clinical Stage I Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage II Gastric Cancer AJCC v8","enrollment":240},{"nctId":"NCT07153783","phase":"NA","title":"Interventional AI-Human Collaboration for Liver Tumor Diagnosis","status":"COMPLETED","sponsor":"Shengjing Hospital","startDate":"2025-09-01","conditions":"Hepatocellular Carcinoma (HCC), Intrahepatic Cholangiocarcinoma (Icc), Hepatic Metastasis","enrollment":10333},{"nctId":"NCT07232056","phase":"NA","title":"Geriatric Oncology Assessment and Coping Skills Training for Older Women on Aromatase Inhibitor Therapy","status":"NOT_YET_RECRUITING","sponsor":"Duke University","startDate":"2026-06-01","conditions":"Breast Cancer, Hormone Receptor Positive, Aromatase Inhibitor-Associated Arthralgia","enrollment":452},{"nctId":"NCT07215364","phase":"NA","title":"Impact of Exercise on Quality of Life of EBC Patients on Treatment With Adjuvant AI With or Without CDK4/6 Inhibitors","status":"NOT_YET_RECRUITING","sponsor":"Spanish Breast Cancer Research Group","startDate":"2026-03","conditions":"Early-stage Breast Cancer","enrollment":74},{"nctId":"NCT06145308","phase":"PHASE2","title":"Precision Treatment of Recurrent/Metastatic Salivary Gland Carcinoma Guided by Molecular Typing","status":"RECRUITING","sponsor":"Peking Union Medical College","startDate":"2023-08-15","conditions":"Salivary Gland Carcinoma, Precision Therapy","enrollment":39},{"nctId":"NCT07062380","phase":"","title":"AI-Based Prediction of HCC Recurrence Patterns After Resection (APAR)","status":"RECRUITING","sponsor":"Tongji Hospital","startDate":"2025-06-10","conditions":"Hepatecellular Carcinoma, Hepatectomy","enrollment":353},{"nctId":"NCT07140107","phase":"NA","title":"Effectiveness of Original vs. AI-Generated Plain Language Summaries of Systematic Reviews","status":"ENROLLING_BY_INVITATION","sponsor":"University of Split, School of Medicine","startDate":"2025-08-14","conditions":"Non-Metastatic Breast Cancer","enrollment":130},{"nctId":"NCT07050225","phase":"NA","title":"Evaluating a Digital Cognitive Training Intervention in Adults With ADHD","status":"NOT_YET_RECRUITING","sponsor":"McMaster University","startDate":"2025-08","conditions":"ADHD","enrollment":52},{"nctId":"NCT05952557","phase":"PHASE3","title":"An Adjuvant Endocrine-based Therapy Study of Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2)","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2023-10-05","conditions":"Breast Cancer, Early Breast Cancer","enrollment":5500},{"nctId":"NCT04068103","phase":"PHASE2, PHASE3","title":"Circulating Tumor DNA Testing in Predicting Treatment for Patients With Stage IIA Colon Cancer After Surgery","status":"ACTIVE_NOT_RECRUITING","sponsor":"NRG Oncology","startDate":"2019-12-16","conditions":"Colon Adenocarcinoma, Stage IIA Colon Cancer AJCC v8","enrollment":635},{"nctId":"NCT06223698","phase":"PHASE3","title":"Optimizing Extended Adjuvant Endocrine Therapy in Patients With Breast Cancer","status":"NOT_YET_RECRUITING","sponsor":"Region Örebro County","startDate":"2025-05-02","conditions":"Breast Cancer","enrollment":3832},{"nctId":"NCT06582446","phase":"PHASE2","title":"Artificial Intelligence to Personalize Prostate Cancer Treatment (the HypoElect Trial)","status":"RECRUITING","sponsor":"German Oncology Center, Cyprus","startDate":"2024-09-16","conditions":"Prostate Cancer","enrollment":30},{"nctId":"NCT06684418","phase":"","title":"Artificial Intelligence-based Model for the Prediction of Occult Lymph Node Metastasis and Improvement of Clinical Decision-making in Non-small Cell Lung Cancer","status":"RECRUITING","sponsor":"Fudan University","startDate":"2024-12-01","conditions":"NSCLC (Non-small Cell Lung Cancer), Artificial Intelligence (AI), Lymphnode Metastasis","enrollment":6000},{"nctId":"NCT04846933","phase":"NA","title":"Multi-layer Data to Improve Diagnosis, Predict Therapy Resistance and Suggest Targeted Therapies in HGSOC","status":"RECRUITING","sponsor":"Turku University Hospital","startDate":"2012-02-01","conditions":"High Grade Ovarian Serous Adenocarcinoma, High Grade Serous Carcinoma","enrollment":200},{"nctId":"NCT06587789","phase":"","title":"Ribociclib in Combination With Adjuvant Endocrine Therapy for Patients With Early High-risk HR+HER2- Breast Cancer","status":"RECRUITING","sponsor":"Second Affiliated Hospital, School of Medicine, Zhejiang University","startDate":"2024-01-01","conditions":"Breast Cancer","enrollment":286},{"nctId":"NCT06341894","phase":"PHASE2","title":"Efficacy and Safety of Dalpiciclib With Endocrine Therapy as Adjuvant Treatment in HR+/ HER2- Early Breast Cancer","status":"RECRUITING","sponsor":"The First Affiliated Hospital with Nanjing Medical University","startDate":"2023-11-17","conditions":"Early Breast Cancer","enrollment":1163},{"nctId":"NCT01307956","phase":"PHASE2","title":"Panitumumab, Combination Chemotherapy, & Radiation Therapy in Esophageal or Gastroesophageal Junction Cancer","status":"TERMINATED","sponsor":"University of Nebraska","startDate":"2011-02-28","conditions":"Adenocarcinoma of the Gastroesophageal Junction, Esophageal Adenocarcinoma, Stage IIA Esophageal Cancer","enrollment":11},{"nctId":"NCT03324932","phase":"PHASE3","title":"Efficacy of Denosumab on Normal BMD in Women Receiving Adjuvant Aromatase Inhibitors for Early Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Kyoto Prefectural University of Medicine","startDate":"2017-09-25","conditions":"Breast Cancer","enrollment":160},{"nctId":"NCT00499083","phase":"PHASE2","title":"Paclitaxel, Cyclophosphamide & Doxorubicin, Autologous Dendritic Cells & Surgery in Stage II/III Breast Cancer (Women)","status":"COMPLETED","sponsor":"University of Nebraska","startDate":"2006-05-01","conditions":"Breast Cancer","enrollment":17},{"nctId":"NCT03786198","phase":"NA","title":"Activity Program During Aromatase Inhibitor Therapy","status":"COMPLETED","sponsor":"Swiss Cancer Institute","startDate":"2019-03-28","conditions":"Early Breast Cancer","enrollment":375},{"nctId":"NCT05870813","phase":"","title":"CLEAR-B: Cancer Landscape - Early Adjuvant Retrospective Registry - Breast Cancer","status":"UNKNOWN","sponsor":"Institut fuer Frauengesundheit","startDate":"2023-03-10","conditions":"Breast Cancer, HER2-negative Breast Cancer, Hormone Receptor Positive Breast Carcinoma","enrollment":3000},{"nctId":"NCT02440230","phase":"PHASE2","title":"Safety of OFS Combined With AI Endocrine Therapy in Chinese Premenopausal Breast Cancer Patients","status":"COMPLETED","sponsor":"Shanghai Jiao Tong University School of Medicine","startDate":"2015-05","conditions":"Breast Cancer","enrollment":110},{"nctId":"NCT05650216","phase":"PHASE2","title":"Camrelizumab Combined With Neoadjuvant Concurrent Chemoradiotherapy for Resectable Locally Advanced ESCC（NICE-RT）","status":"UNKNOWN","sponsor":"Shanghai Chest Hospital","startDate":"2022-12-25","conditions":"Esophageal Squamous Cell Carcinoma","enrollment":50},{"nctId":"NCT04355858","phase":"PHASE2","title":"Molecularly Targeted Umbrella Study in Luminal Advanced Breast Cancer","status":"UNKNOWN","sponsor":"Fudan University","startDate":"2020-05-01","conditions":"Breast Cancer, Metastatic Cancer","enrollment":319},{"nctId":"NCT01613560","phase":"PHASE2","title":"Clinical Study of Adjuvant Therapy on Post-menopausal Women With Breast Cancer Under the Guidance of the Results of Preoperative Endocrinotherapy","status":"UNKNOWN","sponsor":"Tao OUYANG","startDate":"2012-05-05","conditions":"Breast Cancer","enrollment":404},{"nctId":"NCT03795012","phase":"PHASE2","title":"Trial With Eribulin or Eribulin+ Endocrine Therapy in Locally-recurrent or Metastatic Breast Cancer Patients","status":"TERMINATED","sponsor":"MedSIR","startDate":"2019-04-30","conditions":"Breast Cancer","enrollment":22},{"nctId":"NCT04699214","phase":"PHASE2","title":"Endostar Combined With AI Regimen Compared With AI in Adjuvant Treatment","status":"UNKNOWN","sponsor":"Yong Chen","startDate":"2020-09-01","conditions":"Other Disorders of Soft Tissues","enrollment":210},{"nctId":"NCT04152057","phase":"PHASE1, PHASE2","title":"Pyrotinib Maleate Tablets Combined With Albumin Paclitaxel and Trastuzumab for Her2-positive Breast Cancer","status":"UNKNOWN","sponsor":"West China Hospital","startDate":"2019-11","conditions":"Breast Cancer, HER2 Positive, Combination Chemotherapy","enrollment":20},{"nctId":"NCT00096278","phase":"PHASE3","title":"Fluorouracil, Leucovorin, and Oxaliplatin With or Without Bevacizumab in Treating Patients Who Have Undergone Surgery for Stage II or Stage III Colon Cancer","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2004-09-15","conditions":"Colon Adenocarcinoma, Stage IIA Colon Cancer AJCC v7, Stage IIB Colon Cancer AJCC v7","enrollment":2710},{"nctId":"NCT01515800","phase":"NA","title":"S1105: Text-Messaging Intervention to Reduce Early Discontinuation of AI Therapy in Women With Early-Stage Breast Cancer","status":"COMPLETED","sponsor":"SWOG Cancer Research Network","startDate":"2012-05","conditions":"Breast Cancer","enrollment":724},{"nctId":"NCT01896050","phase":"","title":"Loss of Grip Strength, BMI, and Adjuvant Endocrine Therapy Breast Cancer","status":"COMPLETED","sponsor":"University of Michigan Rogel Cancer Center","startDate":"2009-09","conditions":"Breast Cancer, Arthralgia, Obesity","enrollment":115},{"nctId":"NCT00681122","phase":"","title":"CARIATIDE (Compliance of ARomatase Inhibitors AssessmenT In Daily Practice Through Educational Approach)","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2008-05","conditions":"Breast Cancer","enrollment":2600},{"nctId":"NCT01144572","phase":"","title":"Quality of Life in Chinese Postmenopausal HR(+) Early Breast Cancer (EBC) Patients During Adjuvant Aromatase Inhibitors(AIs) Treatment","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2010-07","conditions":"Breast Cancer","enrollment":494},{"nctId":"NCT00004196","phase":"PHASE3","title":"Interferon Alfa-2b in Treating Patients With Melanoma and Early Lymph Node Metastasis","status":"COMPLETED","sponsor":"University of Alabama at Birmingham","startDate":"1999-10","conditions":"Melanoma (Skin)","enrollment":3000},{"nctId":"NCT00935558","phase":"PHASE2","title":"Dendritic Cell Based Therapy for Breast Cancer Patients","status":"WITHDRAWN","sponsor":"Inge Marie Svane","startDate":"2009-07","conditions":"Breast Cancer","enrollment":""},{"nctId":"NCT00769080","phase":"","title":"The Performance of Patient Support Program in Early Stage Breast Cancer","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2008-09","conditions":"Breast Cancer","enrollment":524},{"nctId":"NCT01352091","phase":"PHASE3","title":"Adjuvant AI Combined With Zoladex","status":"UNKNOWN","sponsor":"Fudan University","startDate":"2008-05","conditions":"Breast Cancer","enrollment":670}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":3,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_2","status":"active","brandName":"AI adjuvant therapy","genericName":"AI adjuvant therapy","companyName":"Tao OUYANG","companyId":"tao-ouyang","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Researchers are studying the use of artificial intelligence (AI) to personalize treatment for various types of cancer, including prostate cancer, gastric cancer, and gastroesophageal junction adenocarcinoma. AI is being investigated as an adjuvant therapy in combination with treatments such as androgen deprivation therapy, high-dose-rate interstitial brachytherapy, and radiotherapy.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":false,"trials":true,"score":3}}